How Does Retatrutide Work? GIP, GLP-1 and Glucagon

What receptor agonism means

This page does not define the compound or summarize TRIUMPH. It explains, from the discovery literature, what it means when LY3437943 is described as an agonist of three receptors. The primary source is Coskun and colleagues, Cell Metabolism, 2022. That paper includes authors affiliated with Eli Lilly.¹

A receptor is a protein that can recognize a ligand and transmit a signal. An agonist is a ligand that, on binding, can favor that activation. The signal need not be identical to the natural ligand’s. A cellular assay measures a response under defined conditions; it is not a clinical endpoint.

For peptide identity, see what retatrutide is. For the clinical program, see clinical trials.

The GIP receptor

GIP (glucose-dependent insulinotropic polypeptide) is an incretin. Its receptor has been studied in nutrient-related metabolic physiology. In the LY3437943 design, Coskun and colleagues characterize activity at this receptor as one of three activities of the same peptide. The paper’s title frames the compound as a triple glucagon, GIP, and GLP-1 receptor agonist investigated for glycemic control and weight change — a research framing, not a consumer claim.¹

That characterization does not authorize reducing the pathway to a commercial slogan. It also does not imply that the size of an in-vitro signal predicts a person’s response.

The GLP-1 receptor

GLP-1 (glucagon-like peptide-1) is another incretin. Agonists of this receptor exist as active ingredients of U.S.-approved products; that does not make retatrutide one of those products. In LY3437943, activity at the GLP-1 receptor is part of the triple profile described in 2022.¹

Saying “GLP-1 burns fat” is not a faithful description of the mechanistic evidence. Signaling at this receptor has been studied in several tissues and models. Pulling a marketing sentence from that work omits conditions and limits.

The glucagon receptor

Glucagon acts, among other sites, on the liver and has been studied in relation to energy metabolism. Coskun and colleagues include the glucagon receptor in the LY3437943 profile. That inclusion is what distinguishes, in that literature, triple agonism from dual GIP and GLP-1 agonism.¹

Saying “glucagon melts fat” is not supported as a general mechanistic claim. The discovery paper explains why combining this target with the incretins was scientifically interesting. It does not turn that hypothesis into a simplified popular mechanism.

What combining the three activities means

The 2022 paper presents a single peptide designed to explore, in preclinical models and in a clinical proof of concept, glycemic control and weight change when those three activities coincide. The question is one of molecular design.¹

Combining targets does not prove that more receptors produce a larger clinical effect. The number of targets is not an efficacy scale. This page does not invent potency ratios among receptors: if the Coskun paper reports quantitative pharmacology, that pharmacology should be read in the paper, not reconstructed from memory.

Preclinical versus clinical evidence

Preclinical evidence — binding assays, cellular signaling, and animal models — helps justify moving a peptide into human study. It does not replace a clinical trial. Coskun and colleagues cover both stretches in one paper; that does not make them interchangeable.¹

Clinical evidence begins when there are participants, a protocol, and, if published, a paper with methods and limitations. Urva, Jastreboff, and Rosenstock belong to that stretch. TRIUMPH belongs to Phase 3 and is read on other pages.^2,3,4

A common shortcut is to treat the Cell Metabolism paper as if it already proved the TRIUMPH program. It does not. Another shortcut is to treat a 2026 release as if it confirmed the 2022 mechanism. It does not. Mechanism explains why the peptide was studied; it does not certify a later trial result.

From mechanism to trials

A linear reading, without skipping stages, would be: Coskun (discovery and proof of concept) → Urva (Phase 1b) → Jastreboff and Rosenstock (two distinct Phase 2 trials) → TRIUMPH (Phase 3). Each step answers a different question.^1,2,3,4

Mechanism does not “explain” a TRIUMPH percentage. A TRIUMPH percentage, moreover, is today a sponsor announcement, not a mechanism paper.

What cannot be concluded from mechanism

• FDA approval does not follow from a peptide having three targets.
• Clinical preference over tirzepatide or semaglutide does not follow from receptor count alone.
• A person’s response cannot be predicted from the receptor profile.
• No human-use indication, schedule, or reconstitution follows from this page.

The cluster index is the Retatrutide research hub.